Acquired Aplastic Anaemia
Conditions
Brief summary
To assess the tolerability and efficacy of rabbit antithymocyte globulin (ATG, Thymoglobuline®) with ciclosporin (CSA) in the first line treatment of patients with acquired severe aplastic anaemia (SAA), and patients with non-severe aplastic anaemia (NSAA) and who are transfusion dependent. To compare the response rate of the combination of rabbit ATG (Thymoglobuline® and CSA from this pilot study with the response rate observed in a series of matched AA patients; treated after 1994 with the combination of horse ATG (Lymphoglobuline®) and CSA; obtained from the EBMT database (comparative study).
Interventions
DRUGRabbit ATG, Thymoglobuline (Genzyme)
1. Rabbit ATG, Thymoglobuline® (Genzyme) 1.5 vials/10kg (3.75mg/kg) daily for 5 days given as an intravenous infusion over 12-18 hours. 2. Ciclosporin (CSA) 5mg/kg/day orally from day +1 for a minimum of 6 months
Sponsors
King Faisal Specialist Hospital & Research Center
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
16 Years to 80 Years
Healthy volunteers
No
Inclusion criteria
1. To define aplastic anaemia there must be at least two of the following: (1) haemoglobin \< 10g/dl; (2) platelet count \< 50 x 109/l; (3) neutrophil count \< 1.5 x 109/l, and a hypocellular bone marrow on bone marrow biopsy 2. Time from diagnosis to study registration ≤ 6mths 3. No prior treatment except for haemopoietic growth factors given for no more than 4 weeks, and androgens. 4. Age ≥ 16yrs (≥ 18yrs in Germany in accordance with German law), with no upper age limit.
Exclusion criteria
1. Eligibility for an HLA-matched sibling donor transplant for SAA patients 2. Prior therapy with ATG or CSA 3. Haematopoeitic growth factors more than 4 weeks before study enrollment 4. Diagnosis of Fanconi anaemia, dyskeratosis congenita or congenital bone marrow failure syndrome 5. Evidence of myelodysplastic disease 6. Paroxysmal nocturnal haemoglobinuria with evidence of significant haemolysis, history of PNH associated thrombosis or a PNH clone \> 50% by flow cytometry 7. Diagnosis or previous history of carcinoma (except local cervical, basal cell, squamous cells, or melanoma) 8. Subject is pregnant (e.g. positive HCG test) or is breast feeding 9. Severe uncontrolled infection or unexplained fever \> 38oC 10. Subjects who have hepatic, renal cardiac, metabolic or other concurrent diseases of such severity that life expectancy is less than 3 months
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Response | 2 years | Primary outcome is response at 6 months post ATG treatment |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Over all survival | 2 years | Secondary outcome variables include overall survival and failure free survival at 2 years post ATG treatment |
Outcome results
None listed